PainReform News

PainReform CEO Ilan Hadar Discusses Latest Developments Related To PRF-110 To Help Tackle The Opioid Epidemic

PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Had

BenzingaMay 8 20:39

PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and Its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.com

Yahoo FinanceMay 8 20:30

PainReform Advances Non-Opioid Pain Relief Solution, PRF-110, in Phase III Trials to Combat Opioid Crisis | NASDAQ:PRFV

Proactive InvestorsMay 7 18:24

PainReform Announces Closing of $4 Million Public Offering

TEL AVIV, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established

GlobeNewswireApr 19 02:19

PainReform Ltd. Adjusts Warrant Terms

TipRanksApr 18 04:57

PainReform Prices Its $4M Offering at $0.80 Apiece; Shares Fall

Seeking AlphaApr 16 20:10

PainReform Prices Offering Of 5M Shares And Warrants At $0.80/Share And Accompanying Warrant

PainReform Prices Offering Of 5M Shares And Warrants At $0.80/Share And Accompanying Warrant

BenzingaApr 16 20:03

PainReform to Issue 5M Ordinary Shares, and Warrants to Purchase Up to 5M Shares, at 80 Cents>PRFX

PainReform to Issue 5M Ordinary Shares, and Warrants to Purchase Up to 5M Shares, at 80 Cents>PRFX

Dow JonesApr 16 20:03

PainReform Will Use Proceeds To Advance Clinical Studies, General Corporate Purposes >PRFX

PainReform Will Use Proceeds To Advance Clinical Studies, General Corporate Purposes >PRFX

Dow JonesApr 16 20:03

PainReform to Raise $4M Via Placing>PRFX

PainReform to Raise $4M Via Placing>PRFX

Dow JonesApr 16 20:01

Press Release: PainReform Announces Pricing of $4 Million Public Offering

PainReform Announces Pricing of $4 Million Public Offering TEL AVIV, Israel, April 16, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specia

Dow JonesApr 16 20:00

323 drugs, hurry up! America is facing the biggest “drug shortage” in history...

The US now seems to be facing an unprecedented “drug shortage”...

cls.cnApr 15 14:37

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), PainReform (PRFX) and IN8bio (INAB)

TipRanksApr 11 00:50

Aptevo Therapeutics, TRACON Pharmaceuticals, Biosig Technologies Among Healthcare Movers

Seeking AlphaApr 10 22:02

BSGM, WAVE and TCBP Among Pre-market Losers

Seeking AlphaApr 10 20:22

Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket

Shares of PriceSmart, Inc. (NASDAQ:PSMT) rose sharply in today's pre-market trading as the company posted better-than-expected earnings for its second quarter. The company reported quarterly earnings

BenzingaApr 10 20:12

AEYE, GSIT and VVPR Among Mid-day Movers

Seeking AlphaApr 10 01:05

PainReform's PRF-110 Sets New Pain Relief Benchmark

TipRanksApr 9 21:27

EXCLUSIVE: PainReform's Non-Opiate Post-Surgical Pain Relief Treatment Outperforms Rival Medicine Under Various Testing Conditions

PainReform Ltd (NASDAQ:PRFX) announced results from new studies demonstrating the superior in-vitro release (IVR) rates of PRF-110 compared to topical post-surgical pain management products available

BenzingaApr 9 20:30

EXCLUSIVE: PainReform Tells Benzinga 'Results Indicated That PRF-110 Released Between 34%-77% More Drug Over a Span of 96 Hours Under Various Testing Conditions'

EXCLUSIVE: PainReform Tells Benzinga 'Results Indicated That PRF-110 Released Between 34%-77% More Drug Over a Span of 96 Hours Under Various Testing Conditions'

BenzingaApr 9 20:30